Vertical Longevity Pharmaceuticals, Inc. — SEC Form D Filing

Vertical Longevity Pharmaceuticals, Inc. filed an SEC Form D on September 26, 2026, reporting $110K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 26, 2026
Amount reported
$110K
Round stage
Seed
Industry
Biotechnology
Website
https://vertical-longevity-pharma.com/

What the company does

Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Atherosclerosis is the leading cause of death globally, yet current standard treatments like statins only slow plaque formation without removing existing plaques or addressing the underlying biological cause. This results in persistent cardiac-related deaths.

Solution

Vertical Longevity Pharma is developing the first senolytic vaccine, which uses a virus-like particle to precisely target and clear senescent cells, thereby reversing atherosclerosis by enabling the body to clear established plaques and recover naturally.

Why now

Advances in understanding cellular aging and the role of senescent cells in age-related diseases like atherosclerosis, combined with emerging senolytic therapies, create a timely opportunity for novel vaccine-based interventions.

Verdict

This cleared because the foundational scientific bet on senolytic therapies had reached sufficient proof points to attract early-stage capital, not because the specific vaccine modality was proven. Investors were implicitly betting on the long-term potential of reversing rather than managing chronic age-related disease, accepting the significant scientific and regulatory hurdles inherent to novel biologicals. The limited upside stemmed from the extremely long development timelines and capital requirements typical of pharma, making any early exit improbable and full realization of the vision decades away.

Source: SEC EDGAR Form D filing